Core Viewpoint - Jingtai Technology has successfully delivered an automated workstation for formula stability testing to BASF, marking a significant advancement in chemical automation and validating its technical and commercial capabilities [1][2]. Group 1: Company Achievements - Jingtai Technology's automated laboratory solutions have been instrumental in various fields, including drug development, petrochemicals, new energy, and new materials, providing high-precision research data [2]. - The successful implementation of the collaboration with BASF is attributed to Jingtai's unique modular standard platform and agile customization capabilities, which have been successfully delivered in high-value areas such as new drug development and chemical synthesis [2][3]. - The automated laboratory not only standardizes experimental operations but also generates high-quality structured data, which is essential for developing proprietary AI models in research and development [3]. Group 2: Market Position and Expansion - Jingtai Technology has established a competitive edge in the field of chemical automation, having served major enterprises and top research institutions, including international pharmaceutical companies and Sinopec [3]. - The business model of "standardized platform + agile customization" allows Jingtai to expand its market boundaries from pharmaceutical research to large-scale chemical and new energy sectors, tapping into trillion-level markets [3]. - BASF, as a global leader in the chemical industry, employs approximately 112,000 people and is projected to achieve global sales of €65.3 billion in 2024, highlighting the scale and significance of the partnership with Jingtai Technology [3].

Group 1 - The core viewpoint of the article highlights that Jingtai Holdings (02228) has successfully delivered an automated workstation for formula stability testing to BASF, enhancing BASF's automation system across sample management, testing analysis, and data management [1] - The stock price of Jingtai Holdings increased by 4.52%, reaching HKD 11.8, with a trading volume of HKD 296 million [1] - The automated platform has been successfully delivered in high-value fields such as new drug development, chemical synthesis, and new material discovery [1] Group 2 - On February 5, Jingtai Holdings announced a project agreement and long-term strategic cooperation with Weisheng Pharmaceutical (02561) [1] - The collaboration aims to integrate Jingtai Holdings' AI and robotics drug development platform with Weisheng Pharmaceutical's expertise in the endocrine field, focusing on high clinical value indications and innovative targets [1] - This partnership seeks to advance the early discovery and clinical translation of innovative therapies in the endocrine treatment sector, targeting a market potential worth hundreds of billions [1]

Core Viewpoint - Crystal Tech Holdings (02228) has successfully delivered an automated workstation for formula stability testing to BASF, enhancing BASF's automation system across various high-value fields such as new drug development and chemical synthesis [1] Group 1: Company Developments - Crystal Tech Holdings' stock rose over 4%, reaching 11.8 HKD with a trading volume of 296 million HKD [1] - The automated workstation delivered to BASF supports a comprehensive automation system for sample management, testing analysis, and data management [1] Group 2: Strategic Partnerships - On February 5, Crystal Tech Holdings announced a project agreement and long-term strategic cooperation with Weisheng Pharmaceutical (02561) [1] - The collaboration aims to integrate Crystal Tech's AI and robotics drug development platform with Weisheng's expertise in the endocrine field, focusing on high clinical value indications and innovative targets [1] - This partnership seeks to advance the early discovery and clinical translation of innovative therapies in the endocrine treatment sector, targeting a market potential worth hundreds of billions [1]

Group 1 - The core achievement of the company is the successful delivery of an automated workstation for formulation stability testing to BASF, a global leader in the chemical industry, enhancing BASF's automated system for sample management, testing analysis, and data management [1] - This collaboration signifies a significant advancement in the company's intelligent autonomous laboratory solutions within the chemical automation sector, validating its technical strength and commercial delivery capabilities [1][2] - The company's modular standard platform and agile customization capabilities have been successfully implemented in high-value fields such as new drug development and chemical synthesis, ensuring efficient deployment and stable operation [2] Group 2 - The automated laboratory solutions have been adopted by various large enterprises and top research institutions, including international pharmaceutical companies and major universities, expanding the company's business boundaries from pharmaceutical research to large-scale chemical and new energy markets [3] - The company aims to deepen strategic collaboration with global industry leaders, accelerating the technological iteration of intelligent laboratories and providing core infrastructure for innovation in industrial research efficiency [3] - The integration of AI in research is positioning the company's automated laboratories as essential infrastructure for future AI-driven research, establishing a unique competitive barrier in the market [2]

Group 1 - The core achievement of the company is the successful delivery of an automated workstation for formulation stability testing to BASF, a global leader in the chemical industry, enhancing BASF's automated system for sample management, testing analysis, and data management [1] - This collaboration signifies a significant advancement in the company's intelligent autonomous laboratory solutions within the chemical automation sector, validating its technical strength and commercial delivery capabilities [1][2] - The company's modular standard platform and agile customization capabilities have been successfully implemented in high-value fields such as drug development and chemical synthesis, ensuring efficient deployment and stable operation [2] Group 2 - The automated laboratory solutions have been adopted by various large enterprises and top research institutions, expanding the company's business boundaries from pharmaceutical research to the trillion-dollar markets of chemicals and new energy [3] - The company aims to deepen strategic collaboration with global industry leaders, accelerating the technological iteration of intelligent laboratories and providing core infrastructure for innovation in industrial research efficiency [3] - The integration of AI in research is positioning the company's automated laboratories as essential infrastructure for future AI-driven research, establishing a unique competitive barrier in the market [2]

Core Insights - The company has successfully delivered an automated formulation stability testing workstation to BASF, enhancing BASF's automated system for sample management, testing analysis, and data management [1] - This collaboration marks a significant advancement in the company's intelligent autonomous laboratory solutions within the chemical automation sector, validating its technical strength and commercial delivery capabilities [1][2] Group 1 - The successful implementation of this collaboration is attributed to the unique modular standard platform and agile customization capabilities of the company's intelligent autonomous laboratory [2] - The platform has achieved successful delivery in high-value areas such as new drug development, chemical synthesis, and new material discovery, accumulating substantial experience [2] - The company aims to establish a strong authority in chemical automation, evidenced by its ability to meet stringent global technology standards and achieve near "zero defects" in delivery [2] Group 2 - The company's automated laboratory solutions are currently serving various large enterprises and top research institutions, including international pharmaceutical companies and major universities [3] - The business model of "standardized platform + agile customization" is expanding from pharmaceutical research into the trillion-dollar markets of large chemicals and new energy [3] - The company plans to deepen strategic collaboration with global industry leaders to accelerate the technological iteration and experience accumulation of intelligent laboratories, driving the chemical research into a new era powered by AI and robotics [3]

本自願公告乃由晶泰控股有限公司（「本公司」，連 同 其 附 屬 公 司 統 稱「本集團」） 作 出，以 知 會 股 東 及 潛 在 投 資 者 有 關 本 集 團 的 最 新 業 務 發 展。 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 公 告 全部或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責 任。 XtalPi Holdings Limited 晶泰控股有限公司 （於 開 曼 群 島 註 冊 成 立 之 有 限 公 司） （股 份 代 號：2228） 自願性公告 晶 泰 科 技 機 器 人 實 驗 室 落 地 巴 斯 夫， 全球技術領導力獲化工業頂級背書 本公司董事會（「董事會」）欣 然 宣 布，近 日，本 集 團 已 成 功 向 全 球 化 工 巨 頭 巴 斯 夫(BASF)交 付 了 一 種 配 方 穩 定 性 測 試 自 動 化 工 作 站，助 力 巴 斯 夫 構 建 起「樣 品 管 理－測 試 分 析－數 據 管 理」全 鏈 路 的 自 動 化 ...